Effects of tofersen treatment in patients with SOD1-ALS in a “real-world” setting – a 12-month multicenter cohort study from the German early access program
View Full Paper
Ask AI
Bookmark
Share
Abstract
In April 2023, the antisense oligonucleotide tofersen was approved by the U.S. Food and Drug Administration (FDA) for treatment of
Discussion
No takes yet. Share an insight, caveat, or question.